Oral

White Paper Reveals Striking Data on Health Disparities in American Indian and Alaska Native Communities

Retrieved on: 
Monday, March 20, 2023
Native American, Other Philanthropy, Teens, Healthcare Reform, Public Policy, Government, Children, Dental, Other Consumer, Professional Services, Health, Women, Philanthropy, Seniors, Public Safety, DEI (Diversity, Equity and Inclusion), Men, General Health, Advocacy Group Opinion, Family, Consumer, Other Health, Other Policy Issues, Minter, Dentistry, Society, Partnership, Prevalence, AI, Dentist, Hope, Historical trauma, Data collection, MBA, Multimedia, Infection, Research, Organization, Indian Health Service, Tooth decay, Student, Genocide, Oral, Health care, MPH, Trauma, Women's National Indian Association, Tooth loss, Nursing, Medical device, DMD, MD

Today, CareQuest Institute for Oral Health ®, the Society of American Indian Dentists (SAID), and the National Indian Health Board’s (NIHB) Tribal Oral Health Initiative released a white paper on oral health disparities in American Indian and Alaska Native (AI/AN) communities.

Key Points: 
  • Today, CareQuest Institute for Oral Health ®, the Society of American Indian Dentists (SAID), and the National Indian Health Board’s (NIHB) Tribal Oral Health Initiative released a white paper on oral health disparities in American Indian and Alaska Native (AI/AN) communities.
  • View the full release here: https://www.businesswire.com/news/home/20230320005530/en/
    The white paper, “American Indian and Alaska Native Communities Face a ‘Disproportionate Burden of Oral Disease’: Reversing Inequities Involves Challenges and Opportunities,” includes striking new data from CareQuest Institute’s State of Oral Health Equity in America survey and offers strategic recommendations on how to address disparities and inequities facing AI/AN communities.
  • “The data and research in this white paper affirm the serious health disparities that AI/AN communities have faced for generations due to structural racism and historical trauma,” said CareQuest Institute CEO and President Myechia Minter-Jordan, MD, MBA.
  • Our hope is that the data and recommendations in this white paper help address the deep health inequities facing this population.

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Retrieved on: 
Saturday, March 18, 2023
Attack, Hereditary angioedema, Safety, Bradykinin receptor B2, Softgel, II, Pain, HAE, Oral, United Kingdom, Conference, Pharmaceutical industry

The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.

Key Points: 
  • The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • The presentation slides will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Oral Clinical Nutrition Market Size, Share & Trends Analysis Report By Stage, By Indication, By Sales Channel, By Region And Segment Forecasts, 2023 - 2030

Retrieved on: 
Tuesday, March 14, 2023
Nutrient deficiency, Protein, Conditional sentence, Alzheimer's disease, Government, Electrolyte, Genome Canada, Somatic symptom disorder, Incidence, Clinical, R, Prevalence, Immunity, Hypertension, Ottawa University, White House conference, Vitamin, Cancer, Filament, Abbott, Growth, COVID-19, Dicarboxylic acid, CIHR, Research, CHEO, Sale, Obesity, Oral, Dysphagia, Mineral, Conference, Malnutrition, Food, Vitamin D, IBD, USD, Yogurt, Dietary supplement, Hospital, Pediatrics, Health, Hunger

They also have a wide range of applications in the treatment of chronic diseases such as cancer, neurological conditions and gastrointestinal disorders.

Key Points: 
  • They also have a wide range of applications in the treatment of chronic diseases such as cancer, neurological conditions and gastrointestinal disorders.
  • Such initiative has led to the development of more advanced and effective oral clinical nutrition supplements, which has increased their adoption and growth in the market.
  • Further, the COVID-19 pandemic has had a positive impact on the oral clinical nutrition market.The demand for oral clinical nutrition supplements has increased catering to the issues faced due to malnutrition.
  • Cancer care segment held the largest share in 2022 owing to its rising prevalence and hospital admissions for cancer treatment.

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Molecule, Tissue, Ferret, RNA-dependent RNA polymerase, Omicron, Oral, Pharmacokinetics, Into, MAD, Animal, Irrigation, Mitigation, CET, Heart, Antiviral Research, Potential, Conference, SARS-CoV-2, Plasma, ID, PK, SAD, C24, Patient, Treatment, Adipocyte, RNA, International Conference on Emerging Infectious Diseases, PBO, Medication, Rat, Safety, Half-life, Gland, Viral, ICAR, IC50, COVID-19, UTP, Headache, Pharmaceutical industry, Vaccine, Powder metallurgy, Phosphorus

Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients.

Key Points: 
  • Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients.
  • Additional preclinical data demonstrate that EDP-235’s optimized tissue targeting may help to minimize viral rebound.
  • To evaluate the impact of EDP-235 treatment on SARS-CoV-2 transmission, infected source animals were co-housed with uninfected contact animals 60 hours post-infection.
  • This high throughput screen identified multiple, structurally diverse, non-nucleoside SARS-CoV-2 RdRp inhibitors as potential starting points for hit optimization.

EQS-News: Henkel AG & Co. KGaA: Henkel delivers significant sales increase in 2022 – poised for further growth in fiscal 2023

Retrieved on: 
Saturday, March 11, 2023
Partnership, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, EBIT, Persil, Advertising, Annual, Oral, Supervisory board, EPS, Annual general meeting, Heart, Consumer, Schwarzkopf, Share repurchase, Electricity, Public expenditure, Growth, Culture, Henkel, Šomat, Nursing care plan, Overalls, Human, Investment, Marketing, Consumer Brands Association, BASF, Security (finance), Cryptocurrency, Renewable energy, Video game, Pharmaceutical industry, Music, Retail, Fine chemical, Laundry

The Adhesive Technologies business unit achieved double-digit organic sales growth of 13.2 percent, to which all business areas contributed.

Key Points: 
  • The Adhesive Technologies business unit achieved double-digit organic sales growth of 13.2 percent, to which all business areas contributed.
  • The Laundry & Home Care business unit generated very strong organic sales growth of 6.3 percent, driven particularly by significant growth in the Laundry Care business area.
  • By that, Henkel is creating a multi-category platform for future growth of around 11 billion euros sales in 2022.
  • Henkel also advanced in digitalization and increased the share of digital sales in Group sales to more than 20 percent.

Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 10, 2023
Biotechnology, Pharmaceutical, Health, Cream, Journal, Psoriasis Area and Severity Index, QD, Psoriasis, Nose, Pain, Itch, Body surface area, Oral, Abstract, Headache, Rash, Folliculitis, Pivotal, American Academy, PGA, Pharmacokinetics, Therapy, Irritation, Prescription, Stinger, Food, Composite, Incidence, PASI, Common, BSA, FDA, Convention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, JAAD, Swelling, Pharmaceutical industry, Dietary supplement, Cosmetics, Medical imaging, Dermatology

Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA®(tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in New Orleans, Louisiana.

Key Points: 
  • Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA®(tapinarof) cream, 1% will be presented at the 2023 American Academy of Dermatology Annual Meeting, to be held from March 17-21 in New Orleans, Louisiana.
  • This fall, all of the abstracts will also be published in the Journal of the American Academy of Dermatology (JAAD).
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Visit fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Dermavant Sciences at 1-8 DERMAVANT (1-833-762-8268).

Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)

Retrieved on: 
Thursday, March 2, 2023
Biotechnology, Pharmaceutical, Health, Homocysteine, Medication, Oral, Betaine, Multimedia, Homocystinuria, Full, Use, Patient, NDC, Pharmaceutical industry

Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.

Key Points: 
  • Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.
  • This press release features multimedia.
  • This launch will provide patients with homocystinuria, and the healthcare providers delivering care to those patients, with a safe, efficacious and accessible treatment option.
  • See the Full Prescribing Information and Instructions for Use for Betaine Anhydrous for Oral Solution, 180 grams.

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

Retrieved on: 
Wednesday, March 1, 2023
Clinical trial, Tacrolimus, American Osteopathic Board of Ophthalmology and Otolaryngology, Coronavirus Scientific Advisory Board, DMD, Cone Health Women's Hospital, Associate, UCSF, MHS, Infection, Research, Immunity, Disease, IND, Oral medicine, Harvard School of Dental Medicine, DDS, FIU Herbert Wertheim College of Medicine, FDA, Tufts University School of Dental Medicine, Dentistry, Oral, Division, Hospital, Wake Forest School of Medicine, MPH, Oral Oncology, OLP, Oral and maxillofacial surgery, LIPO, Pharmaceutical industry, Vaccine, Doctor of Philosophy, Brigham

PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.  

Key Points: 
  • PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
  • The five-member Board will initially focus on the development of LP-310, Lipella's product candidate for the treatment of symptomatic oral lichen planus (OLP).
  • Members of the advisory board include:
    Alessandro Villa, DDS, PhD, MPH will serve as the inaugural Chair of the Scientific Advisory Board.
  • Dr. Villa is the Chief of Oral Medicine, Oral Oncology and Dentistry at Miami Cancer Institute and Professor, Herbert Wertheim College of Medicine, Miami, FL.

Los Angeles County’s Covid-19 Test-to-Treat Program With Healthvana Successfully Reaches Underserved Populations by Leveraging Technology

Retrieved on: 
Tuesday, February 28, 2023
General Health, Pharmaceutical, Telemedicine, Virtual Medicine, Data Management, Consumer, Technology, Infectious Diseases, State, Local, Health Technology, Other Consumer, COVID-19, Health, Public Policy, Government, Death, Council of Senior Scholars (Saudi Arabia), Stanford University, Public health, Los Angeles County Department of Health Services, Hospital, Public, Risk, Los Angeles County Department of Public Health, Master of Education, Patient, Oral, Stanford University School of Medicine, Therapy, Becker's Hospital Review, Prescription, PCR, Pharmacy, MPH, Pharmaceutical industry, Tourism, Tutoring, Nursing, MD

This helped people get well and undoubtedly kept people out of the hospitals and saved lives,” said Dr. Barbara Ferrer, Ph.D., M.P.H., M.Ed., Director of the Los Angeles County Department of Public Health.

Key Points: 
  • This helped people get well and undoubtedly kept people out of the hospitals and saved lives,” said Dr. Barbara Ferrer, Ph.D., M.P.H., M.Ed., Director of the Los Angeles County Department of Public Health.
  • Our team is grateful for the innovative leaders from the Los Angeles County Department of Public Health that enabled the program and to the researchers at Stanford University."
  • 90% of patients lived in the highest-vulnerability zip codes as identified by the Los Angeles County Department of Public Health.
  • Program costs include part of the Los Angeles County Department of Public Health clinician salaries, the phone banking salaries, and the Healthvana program costs which are estimated to be less than the treatment of a single hospitalized complex case.

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Retrieved on: 
Tuesday, February 28, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Charles River Laboratories, MD, Collagen, Inflammation, Ageing, Partnership, Annual general meeting, FDA, Society of Toxicology, Oral, RA, Rheumatoid arthritis, SOT, Pharmaceutical industry, Toxicology

MyMD plans to give guidance on the early-stage trials for rheumatoid arthritis (RA) as it develops.

Key Points: 
  • MyMD plans to give guidance on the early-stage trials for rheumatoid arthritis (RA) as it develops.
  • MyMD-1 is currently being evaluated in a Phase 2 study for sarcopenia/frailty, a result of the aging process.
  • It has the potential to become the first drug approved by FDA for that condition.
  • The company plans to complete the Phase 2 sarcopenia trial and share data in the near future.